



February 15, 2019

✓ **BSE Limited,**  
Department of Corporate Services,  
P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
**MUMBAI - 400 001.**

**The National Stock Exchange of India Ltd.,**  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**MUMBAI - 400 051.**

Dear Sir/Madam,

**Sub: Disclosure pursuant to Regulation 30 of the SEBI**  
**(Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Enclosed is a Press Release as regards launch of Clobazam Oral Suspension, 2.5mg/mL (indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients two years of age or older), having received USFDA approval earlier.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

Yours faithfully,  
For **LUPIN LIMITED**

*R.V. Satam*  
*CAES (1973)*  
**R. V. SATAM**  
**COMPANY SECRETARY**



Encl.: a.a.



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

## Lupin launches Clobazam Oral Suspension, 2.5mg/mL

**Mumbai, Baltimore, February 15, 2019:** Pharma major Lupin announced the launch of Clobazam Oral Suspension, 2.5mg/mL, having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin's Clobazam Oral Suspension, 2.5mg/mL is the generic version of Lundbeck Pharmaceuticals LLC's Onfi Oral Suspension, 2.5mg/mL. It is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.

Clobazam Oral Suspension, 2.5mg/mL had annual sales of \$253 million in the US (IQVIA MAT December 2018).

### About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8<sup>th</sup> largest generics pharmaceutical company in terms of market capitalization (28<sup>th</sup> December 2018, Bloomberg) and the 8<sup>th</sup> largest generics pharmaceutical company in terms of revenues (30<sup>th</sup> September 2018, Bloomberg LTM) globally. The Company is the 3<sup>rd</sup> largest pharmaceutical player in the US by prescriptions for the Total Market (IQVIA MAT December 2018); 3<sup>rd</sup> largest Indian pharmaceutical company by global revenues (30<sup>th</sup> September 2018, Bloomberg LTM); 6<sup>th</sup> largest generic pharmaceutical player in Japan (IQVIA MAT December 2018) and 5<sup>th</sup> largest company in the Indian Pharmaceutical Market (IQVIA MAT December 2018).

For the financial year ended 31<sup>st</sup> March, 2018, Lupin's Consolidated sales and Net profits before exceptional items were at Rs. 155,598 million (USD 2.41 billion) and Rs. 13,934 million (USD 216 million) respectively. Please visit <http://www.lupin.com> for more information. You could also follow us on Twitter – [www.twitter.com/lupinlobal](http://www.twitter.com/lupinlobal)

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

**For further information or queries please contact –**

Pooja Thakran  
VP – Corporate Communications  
Email: [poojathakran@lupin.com](mailto:poojathakran@lupin.com)  
Ph: +91-22-66402531 / 8291013225

Arvind Bothra  
Head – Investor Relations  
Email: [arvindbothra@lupin.com](mailto:arvindbothra@lupin.com)  
Ph: +91-22-66408237

*\*Safe Harbor Statement*

*Onfi® is a registered trademark of Lundbeck LLC*